Walter Weber, MD, on Implant-Based Breast Reconstruction Techniques After Mastectomy
ASCO 2026
Walter Weber, MD, of University Hospital Basel, presents data from the international randomized phase III PREPEC trial (OPBC-02), which found prepectoral implant-based breast reconstruction (IBBR) significantly and relevantly improved long-term quality of life—at the cost of a higher risk of loss or replacement of expander or implant—compared to subpectoral IBBR (Abstract 504).
The ASCO Post Staff
Peter Schmid, MD, PhD, FRCP, of Queen Mary University of London, shares more data from the phase III lidERA BC clinical trial. This analysis focused on the efficacy and safety of giredestrant in patients with estrogen receptor (ER)-positive, HER2-negative early breast cancer, looking at both premenopausal and postmenopausal populations (Abstract 502).
The ASCO Post Staff
Erika P. Hamilton, MD, FASCO, of Sarah Cannon Research Institute, talks about a comparison of the efficacy and safety of tucatinib vs placebo combined with trastuzumab and pertuzumab as maintenance therapy for HER2-positive metastatic breast cancer by stratified subgroups (Abstract 1005).
The ASCO Post Staff
Julie R. Brahmer, MD, FASCO, of the Bloomberg–Kimmel Institute for Cancer Immunotherapy, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University School of Medicine, provides expert commentary on the overall survival results from the phase III HARMONi-6 trial presented in this year’s Plenary Session. The study compared ivonescimab plus chemotherapy vs tislelizumab plus chemotherapy in previously untreated patients with advanced squamous non–small cell lung cancer (NSCLC) (Abstract LBA4).
The ASCO Post Staff
Christopher A. Barker, MD, of Memorial Sloan Kettering Cancer Center, reviews the results of the RAMPART study, a phase II, multicenter, single-arm clinical trial evaluating response-adapted definitive radiotherapy in combination with cemiplimab-rwlc for locally advanced, unresectable cutaneous squamous cell carcinoma (CSCC) (Abstract 9506).
The ASCO Post Staff
Shailender Bhatia, MD, of the University of Washington and Fred Hutchinson Cancer Center, presents data from the phase III ADAM trial, a multicenter, randomized, double-blinded, placebo-controlled study of the anti–PD-L1 antibody avelumab in patients with Merkel cell carcinoma and lymph node metastases (Abstract LBA9504).
